Chronic Refractory Cough (CRC) Epidemiology Forecast 2025-2034

Chronic refractory cough affects around 10 million people worldwide. It persists for more than a year and causes significant distress to the patients including loss of sleep, pain, depression, and social isolation. It is estimated that women account for nearly two-thirds of the chronic refractory cough cases.

Chronic Refractory Cough (CRC) Epidemiology Forecast Report Coverage

The “Chronic Refractory Cough (CRC) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of chronic refractory cough (CRC). It projects the future incidence and prevalence rates of chronic refractory cough (CRC) across various populations. The study covers age and type as major determinants of the chronic refractory cough (CRC)-affected population. The report highlights patterns in the prevalence of chronic refractory cough (CRC) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of chronic refractory cough (CRC) in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Chronic Refractory Cough (CRC): Disease Overview

Chronic refractory cough is characterized by a persistent cough that lasts even after guideline-based treatment. It has a significant impact on the patient’s quality of life and healthcare utilization. It is observed in 20-46% of patients visiting specialist cough clinics and is more commonly found in middle-aged and older adults. Chronic refractory cough is often associated with an underlying condition such as asthma, gastroesophageal reflux disease (GERD), or upper airway cough syndrome (UACS). Laryngeal dysfunction or neurological factors may also contribute to the disease.

Chronic Refractory Cough (CRC): Treatment Overview

For the treatment of chronic refractory cough, neuromodulators such as gabapentin or pregabalin are often prescribed to the patients. These drugs target the overactive cough reflex and reduce nerve sensitivity in the throat and airway, helping control the urge to cough. Newer medications like gefapixant, a P2X3 receptor antagonist, block specific nerve receptors responsible for cough reflex activation. Some healthcare providers also recommend speech therapy to help manage cough reflexes.

Epidemiology

The chronic refractory cough (CRC) epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for chronic refractory cough (CRC) by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for chronic refractory cough (CRC) and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• It is estimated that 10 million individuals suffer from chronic refractory cough worldwide, with women accounting for two-thirds of the cases owing to their comparatively more sensitive cough reflex.
• As per a research article published in the ERJ Open Research (2024), chronic refractory cough is reported to be common in patients referred to cough clinics. Among 201 patients treated for chronic cough, only 1.5% were diagnosed with unexplained chronic cough. Using standard criteria, 30.7% of 166 patients met the diagnosis for refractory chronic cough, while stricter criteria identified 27.1% as having the condition.
• A 6-year ambispective cohort study (2023), with 369 patients with RCC (refractory chronic cough) and UCC (unexplained chronic cough), revealed that laryngeal symptoms are predominant in the patients, noted in 95.9% of cases. Common cough triggers were reported to be talking (74.9%), pungent odors (47.3%), eating (45.5%), and cold air (42.8%).

Country-wise Chronic Refractory Cough (CRC) Epidemiology

The chronic refractory cough (CRC) epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of chronic refractory cough varies significantly between countries owing to the differences in environmental exposures, healthcare practices, availability of advanced diagnostic technology, and underlying prevalence of associated conditions, among others. Factors such as smoking rates and air pollution levels also substantially influence the incidence rates of chronic refractory cough. Moreover, regions with higher rates of common triggers for chronic cough (asthma, gastroesophageal reflux disease (GERD), or chronic rhinosinusitis) tend to report greater prevalence.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of chronic refractory cough (CRC) based on several factors.
• Chronic refractory cough (CRC) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of Chronic refractory cough (CRC) are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of chronic refractory cough (CRC) epidemiology in the 8 major markets?
• What will be the total number of patients with chronic refractory cough (CRC) across the 8 major markets during the forecast period?
• What was the country-wise prevalence of chronic refractory cough (CRC) in the 8 major markets in the historical period?
• Which country will have the highest number of chronic refractory cough (CRC) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of chronic refractory cough (CRC) during the forecast period of 2025-2034?
• What are the currently available treatments for chronic refractory cough (CRC)?
• What are the disease risks, signs, symptoms, and unmet needs of chronic refractory cough (CRC)?

This product will be delivered within 3-5 business days.